Latest
Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies|Cargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight LogisticsCargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight Logistics|Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies|Cargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight LogisticsCargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight Logistics
Back to articles
•

Techcyte Secures $15M in Funding to Scale AI-Powered Pathology and Diagnostics Platform

Techcyte just locked in $15M, and it lands at a moment when pathology labs aren’t looking for upgrades, they’re looking for relief. Out of Orem, Utah, a place better known for mountains than microscopes, Techcyte has been quietly training machines to see what overworked labs can’t keep up with anymore, and that tension between demand and capacity is exactly where this story lives. Born in 2013 from University of Utah research by Dr. Mohamed Salama, Ralph Yarro and Rick Smith didn’t just license a white paper on blood cell classification, they leaned into a future where diagnostics wouldn’t bottleneck on human bandwidth, turning $113K into a starting point that feels almost fictional in hindsight.

Fast forward to April 30, 2026, where $15M hits the table led by Van Tuyl Companies, with Zoetis and Mayo Clinic doubling down, bringing total funding to around $50M, and the signal here isn’t volume, it’s conviction, the kind that shows up when a system proves it can carry weight. Ben Cahoon, CEO, has been steering since stepping in from COO/CFO back in 2016, building with the kind of discipline that doesn’t chase noise, while Rick Smith, President, and Ralph Yarro, Chairman, keep the foundation tight, experienced, and deliberately unflashy. On the technical side, Shane Swenson, CTO, is architecting the engine while Dr. Tiffany Chen, CMO, ensures that what the machine sees actually translates into clinical truth, because in this world, close isn’t good enough.

Fusion is where it all comes together, not as branding, but as infrastructure, pulling anatomic and clinical pathology into a single AI-powered platform that threads together whole slide imaging, LIS, EHR, and diagnostics into one continuous motion, with DICOM, HL7, and FHIR speaking fluently behind the scenes. More than 5M AI-assisted diagnoses later, the conversation shifts from possibility to throughput, from promise to pressure-tested output, the kind labs can actually rely on when the queue doesn’t stop.

The tension doesn’t ease up from there, because labs aren’t just busy, they’re strained, with rising volumes, limited specialists, and zero tolerance for error, which turns Techcyte’s real product into reclaimed time for experts who don’t have any left to give. Veterinary is already profitable, while environmental and human health move toward 2027, lining up behind a model that’s proving it can scale without breaking.

Then Mayo Clinic opens the vault with access to a Safe Harbor dataset of more than 17M de-identified slides and reports, and now the system doesn’t just run, it learns at a level that compounds quietly, sharpening accuracy, widening capability, and deepening the moat without needing to announce it. Patterns start to emerge in spaces like this, where the problems aren’t glamorous but the impact is unavoidable, and where the companies willing to sit in that tension long enough end up building something the market can’t ignore.

Techcyte

Techcyte

AI-powered pathology and diagnostics platform (Fusion) integrating whole slide imaging, LIS, EHR, and diagnostics for veterinary, environmental, and human health labs

  • Orem, Utah
  • Founded 2013
Website

Key Executives

  • Mohamed Salama (University of Utah Research Founder)
  • Ralph Yarro (Chairman)
+4 more (coming soon)

Investors

Van Tuyl Companies

Related Articles

Trending

View all posts